Abstract: Adeno-associated virus (AAV) is becoming the most promising vector for tumor gene therapy due to its superiority to other gene-carrying vectors, such as high transferring ability, low pathogenicity, low host immune response, and long-term gene expression. AAV has been successfully used to deliver and transfer a variety of therapeutic genes to cancer cells, including suicide genes, anti-angiogenic genes, and immune-related genes, to inhibit tumor initiation, growth and metastasis. Herein, we review the biological features and advances in research and application of AAV-mediated cancer gene therapy.